Spectinomycin

Summary

Spectinomycin (CHEMBL1167) is an approved small-molecule antimicrobial agent (ATC J01XX04); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01XX04
• Indications: 2 conditions
• Chemistry: 332.35 Da · C14H24N2O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1167
Name	Spectinomycin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	15541
ChEBI	CHEBI:9215
ATC	J01XX04
Molecular formula	C14H24N2O7
Molecular weight	332.35
InChIKey	UNFWWIHTNXNPBV-WXKVUWSESA-N

SMILES: C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O

IUPAC name: (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one

ChEBI definition: A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.

Pharmacological roles (ChEBI): antimicrobial agent, antibacterial drug.

Other ChEBI roles (chemical / environmental): bacterial metabolite.

Also known as: Actinospectacin, Adspec, CHX-3101, Espectinomicina, Prospec, Spectinomycin, Spectinomycine, spectinomycin, SPECTINOMYCINE, SID26754323, SPECTINOMYCIN, SPECTINOMYCIN HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1200407, CHEMBL1443447, CHEMBL1969020, CHEMBL3184600, CHEMBL3989571, CHEMBL4543601

Patent coverage: 17,668 distinct patent families (61,342 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).